BAG1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal T lymphocyte population engineered for loss-of-function analysis of the BAG1 gene. The polyclonal format yields a heterogeneous pool of Jurkat cells harboring diverse Cas9-mediated disruptions in the BAG1 locus, providing a versatile model that avoids confounding clonal effects. These polyclonal knockout cells are suitable for studying BAG1-dependent molecular mechanisms in an immortalized T cell background and can be applied across a wide range of biochemical, cell-based, and pharmacological assays.
The Jurkat host line is an extensively characterized acute T cell leukemia-derived lymphoblastoid cell line that serves as a principal model for T cell receptor signaling, apoptosis, and leukemogenesis. Jurkat cells express key T cell signaling components and respond robustly to stimuli that activate NF-??B, MAPK/ERK, and apoptotic pathways. Their rapid proliferation and consistent genetic background make them an ideal platform for interpreting the consequences of BAG1 disruption in a malignant T lymphocyte context.
BAG1 encodes a multi-functional co-chaperone that interacts with Hsp70, Bcl-2, the 26S proteasome, Raf-1, and the glucocorticoid receptor to coordinate protein folding, apoptosis, and proliferation. It is transcriptionally regulated by HSF1, c-Myc, NF-??B, p53, and estrogen receptor alpha. Through its BAG domain, BAG1 modulates Hsp70 ATPase activity and links chaperone-mediated protein quality control to the ubiquitin-proteasome system. Independently, BAG1 binds Bcl-2 to suppress mitochondrial apoptosis and associates with Raf-1 to enhance ERK1/2 pro-survival signaling. Knockout of BAG1, therefore, perturbs both cytoplasmic chaperone networks and key oncogenic pathways.
In Jurkat T cells, BAG1 disruption sensitizes these leukemia cells to apoptosis by removing a critical block at the level of Bcl-2, while simultaneously attenuating Raf-1?CMEK?CERK growth signals. This dual defect replicates aspects of impaired survival signaling observed in malignancies where BAG1 is overexpressed, such as T cell acute lymphoblastic leukemia and other cancers. Consequently, the knockout model provides a valuable tool to dissect how BAG1 integrates stress responses, proteostasis, and apoptotic thresholds in a transformation-relevant cellular environment.
Researchers can employ BAG1 Knockout Jurkat Polyclonal Cells to investigate mechanisms of apoptosis regulation, chaperone-mediated protein triage, and drug resistance in T cell leukemia. Typical assays include Annexin V apoptosis detection, cell proliferation monitoring, Western blot analysis of Hsp70 client proteins, co-immunoprecipitation of Bcl-2 or Raf-1 complexes, and flow cytometric profiling of signaling nodes. The polyclonal knockout pool is also useful for small-molecule screens targeting BAG1-dependent survival pathways. For additional technical details, please contact Ascent Research.
